CliffBio
small molecule

TEKAMLO

ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE

Loss of exclusivityDecember 2029latest FDA-listed patent expiry
CompanyNovartis →View the full company profile on CliffBio

Drug detail

Brand nameTEKAMLO
Active ingredientALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE
StrengthEQ 300MG BASE;EQ 5MG BASE
Dosage formTABLET
RouteORAL
ModalitySmall molecule
FDA approvalAugust 2010
Marketing statusDISCN

Listed patents

PatentExpiresType
8613949December 2029product

More from Novartis

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

TEKAMLO patent cliff — loss of exclusivity December 2029 | CliffBio